A Reliable Research Partner in Life Science and Medicine

Recombinant Human BCMA/TNFRSF17 Protein (His Tag)

Catalog Number: PKSH033486

Note: Centrifuge before opening to ensure complete recovery of vial contents.

ь.				7.0	
H))	es	cr	m	ŤΤ	nn
	6.2	œ	(0)		11)

Species Human

Source P.Pichia-derived Human BCMA/TNFRSF17 protein Met1-Ala54, with an C-terminal

His

Calculated MW 6.9 kDa
Observed MW 12&15-28 kDa
Accession Q02223

Bio-activity Immobilized Mouse APRIL-Fc(PKSM041367) at 1μg/ml (100 μl/well) can bind

Human BCMA-His(PKSH033486). The ED₅₀ of Human BCMA-His(PKSH033486) is

10.75 ng/ml.

Properties

Purity > 95 % as determined by reducing SDS-PAGE.

Endotoxin < 1.0 EU per µg of the protein as determined by the LAL method.

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

Shipping This product is provided as lyophilized powder which is shipped with ice packs.

Formulation Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.


Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants


before lyophilization.


Please refer to the specific buffer information in the printed manual.

Reconstitution Please refer to the printed manual for detailed information.

Data







Immobilized Mouse APRIL-Fc(PKSM041367) at 1 μ g/ml (100 μ l/well) can bind Human BCMA-His(PKSH033486).The ED₅₀ of Human BCMA-His(PKSH033486) is 10.75 ng/ml.

Background

Elabscience®

Elabscience Biotechnology Co., Ltd.

A Reliable Research Partner in Life Science and Medicine

Tumor necrosis factor receptor superfamily; member 17 (TNFRSF17); also known as B cell maturation antigen (BCMA) or CD269 antigen; is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes; and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily; member 13b (TNFSF13BBAFF); and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members; and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-; TRAF6-; NIK-; and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.